ATRi Development & Biomarker-Led Selection; Bridging the Gap Between the Lab & the Clinic

Time: 9:00 am
day: Day Two


  • Functional genomic screening informs patient selection for biomarker-driven clinical trials of ATR inhibitors (and beyond)
  • Identification of sensitive genetic backgrounds may mitigate known challenges with administering ATR and PARP inhibitor combinations
  • Mechanistic insights lead to development of optimized dosing schedules for ATR inhibitors and their combinations